The growing respiratory market keeps evolving. With a projected growth of 4% for the next 3 to 5 years and a shift in the key innovators focus and a surge in generics medicine more emphasis is put on R&D services and knowledge about DPI.
This shift, primarily driven by the high number of new companies entering the field of inhalation, lead to a change in the required support needed. Specifically; the increasing importance of speed to market as well as the trend towards outsourcing ( do more, work faster and more economically). Further, compounded by clients exploring inhaled treatments for new therapeutic indications the need to work with highly reliable industry partners has become crucial. Hence, time has come for INTO to get established and addressing these challenges in the respiratory market.
INTO is a unique cooperation of leaders in the field of inhalation with each having a proven track record of success with the existing market leaders. With a coherent and focused approach INTO will increase the speed and reduce complexity of DPI development. We will make formulation development simpler, faster, and easier to manage. This by offering a coordinated and aligned suite of services in support of product development, leveraging on our unified set of skills and consolidated expertise.
The establishment of INTO we are able to stay ahead of the market and to optimally address the needs of today’s clients in the field of inhalation. Into will be a unique player in the field of CRO’s, providing end-to-end R&D services with collective accountability. An exciting step into a new direction.
The scope of services provided by INTO ranges from rapid multifactorial Proof of Concepts (PoC’s) to full scale API, excipient, blend and filling design and development and troubleshooting such as consultancy of established programs.
We aim to stay agile and flexible, coming together as needed leveraging our successful experience to accelerate customers’ inhalation development.